Faeth Therapeutics, Inc. (SNSE) Form 8-K — Jun 18, 2026
Faeth Therapeutics entered into a Sales Agreement with TD Securities to establish an at-the-market (ATM) offering program allowing the sale of up to $150 million of common stock. The Agent is entitled to a commission of up to 3.0% on gross sales, though the Company is not obligated to sell any shares and may suspend the program at any time. Separately, on June 15, 2026, the Company completed a mandatory conversion of 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock into 24,435,594 shares of Common Stock.
Key figures
- Gross Proceeds
- 150000000
- Shares Outstanding
- 25778754
- Atm capacity usd
- 150000000
- Conversion ratio
- 1:100
- Common shares issued from conversion
- 24435594
Price after filing
Close on the filing date to close N calendar days later (from $17.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.